MindMed Announces New Employee Inducement Grants
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focusing on brain health disorders, has announced the issuance of inducement grants to three newly hired non-executive employees. The grants consist of options to purchase a total of 70,000 common shares of the Company, effective September 9, 2024. These options have an exercise price equal to the closing price of MindMed's common shares on September 6, 2024, and will vest over a four-year period. The vesting schedule includes 25% vesting on October 1, 2025, with the remaining 75% vesting in substantially equal monthly increments over the following three years, subject to continued employment.
The options were granted outside MindMed's equity incentive plans as a material inducement to employment and were approved by the Company's Compensation Committee on September 6, 2024, in compliance with NASDAQ Stock Market rules.
MindMed (NASDAQ: MNMD), un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi della salute mentale, ha annunciato l'emissione di concessioni di incentivazione a tre nuovi dipendenti non esecutivi. Le concessioni consistono in opzioni per acquistare un totale di 70.000 azioni ordinarie dell'azienda, a partire dal 9 settembre 2024. Queste opzioni hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie di MindMed del 6 settembre 2024 e si attiveranno nel corso di un periodo di quattro anni. Il piano di attivazione prevede un'attivazione del 25% il 1° ottobre 2025, con il restante 75% che si attiva in incrementi mensili sostanzialmente uguali nel corso dei tre anni successivi, soggetto a continuazione del rapporto di lavoro.
Le opzioni sono state concesse al di fuori dei piani di incentivazione azionaria di MindMed come incentivo materiale all'occupazione e sono state approvate dal Comitato Compensazione dell'azienda il 6 settembre 2024, in conformità con le norme del NASDAQ Stock Market.
MindMed (NASDAQ: MNMD), una empresa biofarmacéutica en fase clínica centrada en trastornos de la salud cerebral, ha anunciado la emisión de concesiones de incentivo a tres nuevos empleados no ejecutivos. Las concesiones consisten en opciones para comprar un total de 70,000 acciones comunes de la empresa, efectivas a partir del 9 de septiembre de 2024. Estas opciones tienen un precio de ejercicio igual al precio de cierre de las acciones comunes de MindMed del 6 de septiembre de 2024 y se devengarán durante un período de cuatro años. El calendario de devengo incluye un 25% que se devengará el 1 de octubre de 2025, con el 75% restante devengándose en incrementos mensuales sustancialmente iguales durante los tres años siguientes, sujetos a la continuación del empleo.
Las opciones fueron otorgadas fuera de los planes de incentivos de capital de MindMed como un incentivo material para el empleo y fueron aprobadas por el Comité de Compensación de la compañía el 6 de septiembre de 2024, de acuerdo con las reglas del NASDAQ Stock Market.
MindMed (NASDAQ: MNMD)는 뇌 건강 장애에 초점을 맞춘 임상 단계의 생명공학 회사로서 새롭게 고용된 비임원 직원 3명에게 유인 보너스를 발급했다고 발표했습니다. 이 보너스는 2024년 9월 9일부터 70,000주의 회사 보통주를 구매할 수 있는 옵션으로 구성됩니다. 이 옵션의 행사 가격은 2024년 9월 6일 MindMed의 보통주 종가와 같으며, 4년 동안 단계적으로 부여됩니다. 부여 일정은 2025년 10월 1일에 25%가 부여되고, 나머지 75%는 이후 3년 동안 거의 동일한 월별 증가로 부여됩니다. 단, 고용이 유지되어야 합니다.
이 옵션은 MindMed의 자본 유인 계획 외부에서 고용에 대한 중대한 유인으로 제공되었으며, NASDAQ 주식 시장 규정에 따라 2024년 9월 6일 회사 보상위원회에 의해 승인되었습니다.
MindMed (NASDAQ: MNMD), une entreprise biopharmaceutique en phase clinique axée sur les troubles de la santé cérébrale, a annoncé l'octroi de subventions d'incitation à trois nouveaux employés non exécutifs. Les subventions consistent en des options d'achat d'un total de 70 000 actions ordinaires de l'entreprise, effectives à partir du 9 septembre 2024. Ces options ont un prix d'exercice égal au prix de clôture des actions ordinaires de MindMed du 6 septembre 2024 et s'ouvriront sur une période de quatre ans. Le calendrier de consolidation comprend une consolidation de 25 % le 1er octobre 2025, avec les 75 % restants se consolidant en augmentations mensuelles substantiellement égales au cours des trois années suivantes, sous réserve de maintien de l'emploi.
Les options ont été accordées en dehors des plans d'incitation en capital de MindMed comme un incitatif matériel à l'emploi et ont été approuvées par le comité de rémunération de l'entreprise le 6 septembre 2024, conformément aux règles du NASDAQ Stock Market.
MindMed (NASDAQ: MNMD), ein klinisch tätiges Biopharma-Unternehmen, das sich auf Störungen der Gehirngesundheit konzentriert, hat die Vergabe von Anreizvergütungen an drei neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Diese Vergünstigungen bestehen aus Optionen zum Kauf von insgesamt 70.000 Stammaktien des Unternehmens, effektiv ab dem 9. September 2024. Diese Optionen haben einen Ausübungspreis, der dem Schlusskurs der Stammaktien von MindMed am 6. September 2024 entspricht, und werden über einen Zeitraum von vier Jahren aktiviert. Der Vesting-Zeitplan sieht vor, dass 25% am 1. Oktober 2025 aktiviert werden, während die verbleibenden 75% in den folgenden drei Jahren in erheblich gleichen monatlichen Raten aktiviert werden, vorbehaltlich der Fortsetzung der Beschäftigung.
Die Optionen wurden außerhalb von MindMeds Aktienanreizplänen als wesentlicher Anreiz zur Beschäftigung gewährt und wurden am 6. September 2024 vom Vergütungsausschuss des Unternehmens gemäß den Regeln des NASDAQ Stock Market genehmigt.
- Attraction of new talent with inducement grants
- Long-term employee retention strategy with 4-year vesting schedule
- Alignment of employee interests with shareholders through stock options
- Potential dilution of existing shareholders' equity
- Increased share-based compensation expense
The Options were granted as a material inducement to each employee’s employment and were approved by MindMed's Compensation Committee on September 6, 2024, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The Options were granted outside MindMed's equity incentive plans.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909361119/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
How many employees received inducement grants from MindMed (MNMD) in September 2024?
What is the total number of common shares covered by the options granted by MindMed (MNMD) in this announcement?
When will the options granted by MindMed (MNMD) begin to vest?
Were the inducement grants issued under MindMed's (MNMD) existing equity incentive plans?
